Single agent gemcitabine as effective and low-cost second line treatment, in patients with non-targetable advanced wild-type EGFR, negative ALK non-small cell lung cancer after platinum failure / Silvia, Rinaldi; Christian, Grohé; Thomas, Newsom-Davis; Alfredo, Addeo; Federica, Barbotti; Michela, Tiberi; Giulia, Marcantognini; Paola, Mazzanti; Berardi, Rossana. - In: ONCOTARGETS AND THERAPY. - ISSN 1178-6930. - (In corso di stampa).
Single agent gemcitabine as effective and low-cost second line treatment, in patients with non-targetable advanced wild-type EGFR, negative ALK non-small cell lung cancer after platinum failure
Rossana Berardi.
In corso di stampa
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
